Fact CheckerSign in

NCT05600933Enrolling by invitation

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Source: ClinicalTrials.gov · Last updated 16 Oct 2026

Brief summary (registry, in English)

Background: Many advances have been made in cancer treatments, but more research is needed. Comparing samples of cancerous tissue to samples of normal, noncancerous tissues may help find differences between them. These differences may help researchers find new ways to treat cancer. Objective: To collect tissues and blood samples from people with known or suspected cancer. The samples will be used to help identify new targets for cancer treatments. Eligibility: People aged 18 years and older with a known or suspected cancer that requires surgery or biopsy. Design: Participants will be screened. They will answer questions about their health. They can do this on the phone or in person. Researchers will collect information from participants medical records. Data may include information about any prior or current cancers. Data about other medical conditions may also be collected. Participants will have blood drawn. Some of the blood will be tested for HIV and hepatitis B and C. Some of the blood will be used for genetic research. Participants will have tissue samples collected during surgeries or biopsies. These are procedures the participants would have had as part of their standard care. No new procedures will be done just for this study. Researchers may also seek out samples from prior procedures the participant had done. Participants will remain in the study for 6 months. They may have blood drawn again. Researchers may also collect tissue samples from any procedures performed during that time.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
1200 (estimated)
First submitted
25 Oct 2022
Start date
15 May 2023
Primary completion date
15 Jun 2033
Lead sponsor
National Cancer Institute (NCI)
NCT number
NCT05600933

What you commit to

  • Study type: Observational
  • Planned participants: 1200
  • From 15 May 2023 to the primary completion date, 15 Jun 2033
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • INCLUSION CRITERIA:
  • Age \>= 18 years
  • Willing to undergo serologic testing for HIV, hepatitis B and C
  • Participants who have a known or suspected cancer that requires surgery or biopsy as a part of the standard of care diagnosis, treatment and/or follow up.
    • Note: Participants will not be enrolled exclusively for the procurement of tissue samples.
    • -Able and willing to sign an informed consent document.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Institutes of Health Clinical Center
Coordinator of this site? Confirm its status
BethesdaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.